Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Chris Calabrese ,Linkedin ,Nasdaq ,Fulcrum Therapeutics Inc ,Lifesci Advisors ,Stock Incentive Plan ,Nasdaq Listing Rule ,Sci Advisors ,Region ,